## Maximilian Niyazi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6086048/publications.pdf Version: 2024-02-01

		159358	168136
123	3,618	30	53
papers	citations	h-index	g-index
131	131	131	4476
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	ESTRO-ACROP guideline "target delineation of glioblastomas― Radiotherapy and Oncology, 2016, 118, 35-42.	0.3	286
2	Prognostic Significance of Dynamic <sup>18</sup> F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. Journal of Nuclear Medicine, 2015, 56, 9-15.	2.8	144
3	Current concepts in clinical radiation oncology. Radiation and Environmental Biophysics, 2014, 53, 1-29.	0.6	143
4	FET–PET for malignant glioma treatment planning. Radiotherapy and Oncology, 2011, 99, 44-48.	0.3	125
5	Dynamic <sup>18</sup> F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. Journal of Nuclear Medicine, 2014, 55, 198-203.	2.8	123
6	Irradiation and Bevacizumab in High-Grade Glioma Retreatment Settings. International Journal of Radiation Oncology Biology Physics, 2012, 82, 67-76.	0.4	119
7	Therapeutic options for recurrent malignant glioma. Radiotherapy and Oncology, 2011, 98, 1-14.	0.3	113
8	Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiation Oncology, 2013, 8, 296.	1.2	88
9	Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov. Radiation Oncology, 2017, 12, 1.	1.2	87
10	Current status and recent advances in reirradiation of glioblastoma. Radiation Oncology, 2021, 16, 36.	1.2	80
11	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 2021, 23, 881-893.	0.6	75
12	Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. Cancers, 2019, 11, 160.	1.7	68
13	Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. Journal of Neuro-Oncology, 2014, 117, 337-345.	1.4	66
14	Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. Radiotherapy and Oncology, 2019, 131, 202-207.	0.3	65
15	Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease. Strahlentherapie Und Onkologie, 2018, 194, 196-205.	1.0	63
16	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology, 2016, 16, 593-598.	0.5	58
17	Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiation Oncology, 2021, 16, 43.	1.2	58
18	MiRNA expression patterns predict survival in glioblastoma. Radiation Oncology, 2011, 6, 153.	1.2	50

#	Article	IF	CITATIONS
19	FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiotherapy and Oncology, 2012, 104, 78-82.	0.3	50
20	First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. Radiation Oncology, 2020, 15, 74.	1.2	50
21	Brain Necrosis in Adult Patients After Proton Therapy: Is There Evidence for Dependency on Linear Energy Transfer?. International Journal of Radiation Oncology Biology Physics, 2021, 109, 109-119.	0.4	43
22	ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiotherapy and Oncology, 2021, 156, 80-94.	0.3	41
23	Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1–3 cerebral metastases. Radiation Oncology, 2014, 9, 105.	1.2	39
24	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiotherapy and Oncology, 2018, 127, 121-127.	0.3	37
25	Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors. Cancers, 2021, 13, 1523.	1.7	37
26	Single isocenter stereotactic radiosurgery for patients with multiple brain metastases: dosimetric comparison of VMAT and a dedicated DCAT planning tool. Radiation Oncology, 2019, 14, 103.	1.2	36
27	18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. Journal of Nuclear Medicine, 2017, 58, 584-589.	2.8	36
28	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget, 2016, 7, 45764-45775.	0.8	35
29	Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET. Journal of Neuro-Oncology, 2012, 110, 389-395.	1.4	34
30	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiation Oncology, 2017, 12, 176.	1.2	34
31	Reâ€irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score—report of the Radiation Oncology Group ( <scp>ROG</scp> ) of the German Cancer Consortium ( <scp>DKTK</scp> ). Cancer Medicine, 2018, 7, 1742-1749.	1.3	34
32	Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. Radiotherapy and Oncology, 2019, 138, 99-105.	0.3	34
33	Expert consensus on re-irradiation for recurrent glioma. Radiation Oncology, 2017, 12, 194.	1.2	32
34	Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiation Oncology, 2014, 9, 299.	1.2	30
35	Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stageÂlll non-small cell lung cancer. Strahlentherapie Und Onkologie, 2018, 194, 79-90.	1.0	30
36	Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiotherapy and Oncology, 2020, 142, 154-161.	0.3	30

#	Article	IF	CITATIONS
37	Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences. Cancers, 2021, 13, 1767.	1.7	30
38	Adjuvant radiotherapy after breast conserving surgery – A comparative effectiveness research study. Radiotherapy and Oncology, 2015, 114, 28-34.	0.3	29
39	Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?. Oncotarget, 2016, 7, 2313-2328.	0.8	29
40	Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Journal of Neuro-Oncology, 2016, 130, 591-599.	1.4	28
41	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. Journal of Neurology, 2017, 264, 350-358.	1.8	27
42	Current status and recent advances in resection cavity irradiation of brain metastases. Radiation Oncology, 2021, 16, 73.	1.2	27
43	Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis. Radiation Oncology, 2020, 15, 37.	1.2	26
44	Patient positioning and immobilization procedures for hybrid MR-Linac systems. Radiation Oncology, 2021, 16, 183.	1.2	26
45	Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort. Radiation Oncology, 2014, 9, 128.	1.2	24
46	Novel rotatable tabletop for total-body irradiation using a linac-based VMAT technique. Radiation Oncology, 2019, 14, 244.	1.2	24
47	FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?. Radiation Oncology, 2021, 16, 46.	1.2	24
48	Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate. Radiation Oncology, 2022, 17, 53.	1.2	24
49	Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas. Acta Neurochirurgica, 2015, 157, 1757-1764.	0.9	23
50	Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging. Clinical Lung Cancer, 2017, 18, e243-e249.	1.1	23
51	Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? – A recurrence pattern analysis. Radiotherapy and Oncology, 2020, 145, 49-55.	0.3	23
52	Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer. Radiation Oncology, 2021, 16, 133.	1.2	23
53	Visualization, imaging and new preclinical diagnostics in radiation oncology. Radiation Oncology, 2014, 9, 3.	1.2	21
54	A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients. International Journal of Clinical Oncology, 2016, 21, 642-650.	1.0	21

#	Article	IF	CITATIONS
55	18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?. Journal of Neuro-Oncology, 2017, 132, 277-286.	1.4	21
56	Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold. Strahlentherapie Und Onkologie, 2019, 195, 13-20.	1.0	20
57	Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer. Strahlentherapie Und Onkologie, 2016, 192, 875-885.	1.0	19
58	Temozolomide during radiotherapy of glioblastoma multiforme. Strahlentherapie Und Onkologie, 2017, 193, 890-896.	1.0	19
59	The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?. Neuro-Oncology, 2017, 19, 1698-1699.	0.6	19
60	68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases. Clinical Nuclear Medicine, 2019, 44, 412-413.	0.7	19
61	Distant metastasis time to event analysis with CNNs in independent head and neck cancer cohorts. Scientific Reports, 2021, 11, 6418.	1.6	19
62	Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks. Radiation Oncology, 2020, 15, 117.	1.2	18
63	Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma. Radiation Oncology, 2013, 8, 287.	1.2	17
64	Early treatment of complex located pediatric lowâ€grade gliomas using iodineâ€125 brachytherapy alone or in combination with microsurgery. Cancer Medicine, 2016, 5, 442-453.	1.3	17
65	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. Radiation Oncology, 2019, 14, 184.	1.2	17
66	State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey. European Journal of Cancer, 2019, 108, 50-54.	1.3	17
67	Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. Breast Care, 2018, 13, 285-291.	0.8	16
68	Recurrence pattern analysis after [68Ga]-DOTATATE-PET/CT -planned radiotherapy of high-grade meningiomas. Radiation Oncology, 2018, 13, 110.	1.2	16
69	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	1.0	16
70	MR-guided stereotactic body radiation therapy for primary cardiac sarcomas. Radiation Oncology, 2021, 16, 60.	1.2	15
71	MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience. Radiation Oncology, 2022, 17, 8.	1.2	15
72	Feasibility study on image guided patient positioning for stereotactic body radiation therapy of liver malignancies guided by liver motion. Radiation Oncology, 2016, 11, 88.	1.2	14

#	Article	IF	CITATIONS
73	Radiotherapy of spinal cord gliomas. Strahlentherapie Und Onkologie, 2016, 192, 139-145.	1.0	14
74	Offline and online LSTM networks for respiratory motion prediction in MR-guided radiotherapy. Physics in Medicine and Biology, 2022, 67, 095006.	1.6	14
75	Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 150-155.	1.0	13
76	Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study. Radiotherapy and Oncology, 2017, 122, 2-10.	0.3	13
77	Impact of surface-guided positioning on the use of portal imaging and initial set-up duration in breast cancer patients. Strahlentherapie Und Onkologie, 2019, 195, 964-971.	1.0	13
78	Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. Radiation Oncology, 2018, 13, 25.	1.2	12
79	Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond. Frontiers in Oncology, 2021, 11, 612354.	1.3	12
80	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. Cancers, 2022, 14, 53.	1.7	12
81	Stereoscopic X-ray imaging, cone beam CT, and couch positioning in stereotactic radiotherapy of intracranial tumors: preliminary results from a cross-modality pilot installation. Radiation Oncology, 2016, 11, 158.	1.2	11
82	Medulloblastoma in adults. Strahlentherapie Und Onkologie, 2018, 194, 225-234.	1.0	11
83	SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine. Radiation Oncology, 2020, 15, 165.	1.2	11
84	Simultaneous stereotactic radiosurgery of multiple brain metastases using single-isocenter dynamic conformal arc therapy: aÂprospective monocentric registry trial. Strahlentherapie Und Onkologie, 2021, 197, 601-613.	1.0	11
85	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	1.1	11
86	Multifocal high-grade glioma radiotherapy safety and efficacy. Radiation Oncology, 2021, 16, 165.	1.2	11
87	Dose optimization of total or partial skin electron irradiation by thermoluminescent dosimetry. Strahlentherapie Und Onkologie, 2018, 194, 444-453.	1.0	10
88	Towards optimal stopping in radiation therapy. Radiotherapy and Oncology, 2019, 134, 96-100.	0.3	10
89	Hippocampal EUD in primarily irradiated glioblastoma patients. Radiation Oncology, 2014, 9, 276.	1.2	9
90	Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries. Strahlentherapie Und Onkologie, 2016, 192, 507-515.	1.0	9

#	Article	IF	CITATIONS
91	MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients. Radiation Oncology, 2022, 17, 43.	1.2	9
92	Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study. Radiation Oncology, 2020, 15, 19.	1.2	8
93	Longitudinal [18F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. Biomedicines, 2022, 10, 738.	1.4	8
94	Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy. BMC Cancer, 2016, 16, 216.	1.1	7
95	Use of diffusion-weighted MRI to modify radiosurgery planning in brain metastases may reduce local recurrence. Journal of Neuro-Oncology, 2017, 131, 549-554.	1.4	7
96	Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. PLoS ONE, 2019, 14, e0216111.	1.1	7
97	Innovative radiation oncology Together– Precise,ÂPersonalized,ÂHuman. Strahlentherapie Und Onkologie, 2021, 197, 1043-1048.	1.0	7
98	The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project. Technology in Cancer Research and Treatment, 2016, 15, 365-376.	0.8	6
99	Timing of Failure in Limited Disease (Stage I-III) Small-Cell Lung Cancer Patients Treated with Chemoradiotherapy: A Retrospective Analysis. Tumori, 2013, 99, 656-660.	0.6	5
100	Radiotherapy in oncological emergencies: fast-track treatment planning. Radiation Oncology, 2020, 15, 215.	1.2	5
101	Long-term outcome of stereotactic brachytherapy with temporary lodine-125 seeds in patients with WHO grade II gliomas. Radiation Oncology, 2020, 15, 275.	1.2	5
102	Current status and developments of German curriculum-based residency training programmes in radiation oncology. Radiation Oncology, 2021, 16, 55.	1.2	5
103	Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers. JCO Clinical Cancer Informatics, 2021, 5, 315-325.	1.0	5
104	Risk Stratification Using 18F-FDG PET/CT and Artificial Neural Networks in Head and Neck Cancer Patients Undergoing Radiotherapy. Diagnostics, 2021, 11, 1581.	1.3	5
105	Combining inter-observer variability, range and setup uncertainty in a variance-based sensitivity analysis for proton therapy. Physics and Imaging in Radiation Oncology, 2021, 20, 117-120.	1.2	5
106	Single-isocenter stereotactic radiosurgery for multiple brain metastases: Impact of patient misalignments on target coverage in non-coplanar treatments. Zeitschrift Fur Medizinische Physik, 2022, 32, 296-311.	0.6	5
107	Mammary Chain Irradiation in Left-Sided Breast Cancer: Can We Reduce the Risk of Secondary Cancer and Ischaemic Heart Disease with Modern Intensity-Modulated Radiotherapy Techniques?. Breast Care, 2021, 16, 358-367.	0.8	4
108	TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?. Frontiers in Oncology, 2021, 11, 645316.	1.3	4

#	Article	IF	CITATIONS
109	Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease. Frontiers in Oncology, 2021, 11, 667993.	1.3	4
110	Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas. Radiation Oncology, 2021, 16, 40.	1.2	3
111	A Privacy-Preserving Log-Rank Test for the Kaplan-Meier Estimator With Secure Multiparty Computation: Algorithm Development and Validation. JMIR Medical Informatics, 2021, 9, e22158.	1.3	3
112	Optimizing the Analytical Value of Oncology-Related Data Based on an In-Memory Analysis Layer: Development and Assessment of the Munich Online Comprehensive Cancer Analysis Platform. Journal of Medical Internet Research, 2020, 22, e16533.	2.1	3
113	Novel modified patient immobilisation device with an integrated coil support system for MR-guided online adaptive radiotherapy in the management of brain and head-and-neck tumours. Technical Innovations and Patient Support in Radiation Oncology, 2021, 20, 35-40.	0.6	3
114	Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiation Oncology, 2022, 17, 79.	1.2	3
115	Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort. Journal of Cancer, 2016, 7, 2012-2017.	1.2	2
116	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.3	2
117	Multimodal therapy of cavernous sinus meningioma: impact of surgery and 68Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcome. Neuro-Oncology Advances, 2021, 3, vdab114.	0.4	2
118	Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status. Neuro-Oncology Advances, 2020, 2, vdaa137.	0.4	2
119	[F18] FDC-PET/CT for manual or semiautomated GTV delineation of the primary tumor for radiation therapy planning in patients with esophageal cancer: is it useful?. Strahlentherapie Und Onkologie, 2021, 197, 780-790.	1.0	1
120	X-change symposium: status and future of modern radiation oncology—from technology to biology. Radiation Oncology, 2021, 16, 27.	1.2	1
121	Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients—a report of the PET/RANO group†18F-fluciclovine and target volume delineation. Neuro-Oncology, 2021, 23, 1410-1411.	0.6	1
122	Accounting for uncertainties in the position of anatomical barriers used to define the clinical target volume. Physics in Medicine and Biology, 2021, 66, 15NT01.	1.6	1
123	4-miRNA signature combined with MGMT methylation status in glioblastoma: A multicentric retrospective biomarker analysis with accompanying prospective cohort study Journal of Clinical Oncology, 2020, 38, 2517-2517.	0.8	О